FindTrial
Sign In

Usefulness of skin injections of platelet rich plasma in the treatment of melasma

Role of platelet rich plasma therapy as an adjuvant in treatment of melasma

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/02/017607
Enrollment
30
Registered
2019-02-12
Start date
Unknown
Completion date
Unknown
Last updated
2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L814- Other melanin hyperpigmentation

Interventions

Intervention1: Platelet rich plasma and hydroquinone: Microinjections of platelet rich plasma to the randomly selected side of the face with melasma and Hydroquinone application on both sides of the f

Sponsors

Chingshubam Bikash Singh
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients diagnosed clinically with melasma Patients more than 18 years of age of both sexes

Exclusion criteria

Exclusion criteria: Pregnant and lactating women Women on oral contraceptives Depigmenting treatment in the past 1 month Active facial skin infection

Design outcomes

Primary

MeasureTime frame
Efficacy of platelet rich plasma therapy with hydroquinone versus hydroquinone alone in patients of melasmaTimepoint: Better improvement in modified melasma area severity index with platelet rich plasma and hydroquinone combonation at the end of 3 months—

Secondary

MeasureTime frame
Patients satisfaction with PRP therapy and hydroquinone versus hydroquinone aloneTimepoint: Better patient satisfaction with PRP and hydroquinone combination therapy at the end of 3 months—

Countries

India

Contacts

Public ContactBikash Chingshubam

Delhi university

rashmisarkar@gmail.com00919818244340

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026